Blood-brain barrier company to-BBB moves into commercialization mode with new CEO Willem van Weperen
"I am immensely proud to join to-BBB at a moment that the G-Technology opens many different avenues to treat patients with serious CNS diseases.” says Willem van Weperen. “The last few years, the team of to-BBB has built a strong scientific foundation under the leadership of Pieter Gaillard. With such momentum in the company it is a privilege to help move development forward towards the clinic."
Pieter Gaillard, CSO and founder of the company, is excited that Willem van Weperen has chosen to join the company now that the first Proof of Concept data of the recently in-licensed G-Technology look very promising. “We can now study a range of existing compounds formulated in our brain targeted liposomes. Furthermore, while many blood-brain barrier initiatives have been struggling with immunogenicity, the glutathione-based G-Technology seems to overcome this hurdle."
Based on the current Proof of Concept data with the G-Technology and on existing opportunities, the company will focus its in-house development efforts on brain tumors, Alzheimer’s disease and also on Lysosomal Storage Diseases. to-BBB believes there are also good partnering opportunities in these disease areas, as well as in other CNS areas, like pain, MS, Parkinson and viral encephalitis.
Most read news
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.